Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Humana Inc (HUM) vs New York Times Co (NYT) Price & Performance

Humana IncTrade
New York Times CoTrade

Price performance (Past 24H)

Key statistics

Humana Inc vs New York Times Co — how do they compare? Humana Inc trades at $406.53 (market cap $47.81B), while New York Times Co trades at $74.98 (market cap $12.29B). The key difference: Humana Inc is far larger — about 3.9× New York Times Co's market cap, and New York Times Co pays the higher dividend (1.21%). Which is the better fit depends on your goals.

HUMNYT
Market Cap
$47.81B$12.29B
Sector
HealthMedia
52-Week High
$409.42$85.86
52-Week Low
$163.67$51.43
Enterprise Value
$56.85B$11.68B
Dividend Yield
0.89%1.21%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Humana Inc

Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.

The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.

New York Times Co

The New York Times Company (NYSE: NYT) trades at $75.44, down 0.65% today, with a bullish technical signal and strong fundamentals. Revenue grew to $2.82B in 2025, with net income reaching $344M and profit margins expanding to 12.17%. Recent quarters show consistent earnings beats, and the company announced a $0.23 dividend payable July 23, 2026. Positive cash flow from operations of $584M supports financial health, while analyst consensus price target is $78.00.

Outlook remains positive with steady revenue growth and profitability, though high valuation multiples (P/E 32.59) pose risks. Key catalysts include Q2 2026 earnings on August 5, 2026, and ongoing digital subscription growth. Risks involve regulatory pressures from recent subpoenas to journalists and competitive media landscape. Institutional sentiment is mixed with 29% buy ratings, suggesting cautious optimism for near-term performance.

Returns comparison

Trailing returns across standard periods

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM

About New York Times Co

New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.

Read more on NYT